RACHEL ABRAMCZYK
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism BRYN MAWR, PA NPI 1609360791
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism PA Novo Nordisk AS All categories
General Payments — all program years on this page
$3,426.84
- Category: General Payments
- Program years: PY2019–2024
- Record count: 137
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,123.78 across 95 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,123.78 | 95 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $374.85 | 19 |
| Lilly USA, LLC | $289.45 | 12 |
| Abbott Laboratories | $257.80 | 12 |
| Amgen Inc. | $165.88 | 7 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $105.72 | 5 |
| Corcept Therapeutics | $87.92 | 3 |
| ABBVIE INC. | $80.89 | 4 |
| Kyowa Kirin, Inc. | $80.06 | 3 |
| Medtronic, Inc. | $79.72 | 3 |
| IBSA Pharma Inc. | $72.18 | 3 |
| Tandem Diabetes Care, Inc. | $66.67 | 2 |
| SANOFI-AVENTIS U.S. LLC | $64.24 | 3 |
| DEXCOM, INC. | $53.69 | 2 |
| Insulet Corporation | $48.48 | 2 |
| Amphastar Pharmaceuticals, Inc. | $47.01 | 3 |
| Astellas Pharma US Inc | $41.88 | 2 |
| TOLMAR, INC. | $32.34 | 2 |
| Ascensia Diabetes Care US Inc. | $29.37 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $24.20 | 1 |
| Xeris Pharmaceuticals, Inc. | $23.75 | 1 |
| Radius Health, Inc. | $23.48 | 1 |
| BETA BIONICS, INC. | $21.48 | 1 |
| Almatica Pharma Inc. | $18.19 | 1 |
| Ultragenyx Pharmaceutical Inc. | $17.54 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $16.99 | 1 |
By program year
Records — PY2024 (95)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.